127 471

&ittSCXl IF. Nllr- A=. fblsti LR*. HOlsti P*.

*Helsinki University Central University Central Hospital, ****%ational Institute of Health

Weperformed a 3-am&phase III studybebman 1982 and1990, to evaluatelcwdcee interferm as a maintenancetherapyinmallcellluugcancer(SUC) follouing inductice chemtherapy and consolidation ra- diotherapy. All patients received4 cycles of induc- timchsmtherapy (CT) (cycl 'de, vincristine etqmsida), follmvedby spli~adiotherapy (Wj (55 Qy/2OF/7 wk). 410 patients were entered in this study. 237 reqaxded (CR+PR) tothe induction and cmsolidaticmtherapyandwere rarxdanly assigned to Arm 11 lay &se nIEN4(91 patients); Arm 2: xnainten- ~Cl?,6cyclesCAP(cyclcpho@xk~i~in, cisplatin) (59 patients); or Arm 3: control arm (no mintenancetreatmant) (87+iGFs~. Halfwaythrcugh the study the C&P arm was discontinued. 25/53 patients alive in the IEN am and 16/36 alive in the CAP arm

""1 leted the full courseofmaintenance therapy. 44

patents in the 0-armwsre alive 6 mths after rau- danizatim. There was m significant difference in me- dian survival between the different arm of the (IFN annllm, CAP arm11Im. 0-armlOm, ; but a clearly significantdifferencewas seen inlong- termsurvival, favour nIENwaaintenance

years (p= o.~=x5 was acceptable in both

treatmentMns.Alltreatmentsweregivenonanout- patientbasie.Our results suggest a role fornIEN% mintaining a clinicallydiseas~free status achieved with other treatmentxmdalities, in SCLC.

473

Dose Intensity (DI) of the CAVE regimen in SCLC is important for achieving a higher response rate (R). F. Sinea’, R. Lewensohn*, Ft. Westerberg3.

’ Dpt of Lung Medicine, Huddinge Hospital, * Dpt of Oncology,

Karolinska Hospital and 3 Bristol-Myers, Stockholm - Sweden.

Sixty-three patients with SCLC, 38 LD and 25 ED were treated in the department of lung medicine, Huddinge Hospital - Stockholm, between 1988 and 1990 with qcbphosphamkle (C), doxorubiiin (A), vincrtstin (C) and etoposbe (E). The pats were analyzed retrospectively concerning DI of chemotherapy (CT) during inductfbn treatment (3 CT courses), CR + PR, survival and toxicity. The overall R was 57%. medium survival (S) 289 d.. median DI factor 0.7 (projected DI = 1.0). Toxicity was scarce suggesting that the actual CT deffvered had low intensfty” with modest R. No correlation was found between R and toxkztty. There was a correlatbn between the DI factor of all four drugs together and R. InCreasing DI in the range 0.280 - 0.849 and 0.780 - 0.920 resulted in response rates of 38% and 9O%.respectively Chi-square analysis revealed a sfgntfbant improvement of R when the cut-off value for the DI factor was fffed to 0.8 (P = 0.03) or 0.75 (P = 0.02). No such correlatbn could, however, be demonstrated between DI and S. An improved S w&however,~suggested when the cut-off value for the DI factor was ftxed to 0.75 buf the dterence between the groups was not statlstbatty sfgnlfbant. Thus a correlation between DI and R could be demonstrated in this retmspectfvely analyzed low inter&y’ CAVE regfmen.

472

EXTENDED ADMINISTRATION OF ORAL CYCLOPHOSPHAMIDE C) AmRo$L ETOPOSIDE (E) FOR THE &zEA

STAGE IV NON-SMALL CELL LUNG CANCER - A SOUTHWEST ONCOLOGY GROUP STUDY. Steven M. Grunber Robert Livingston. Fc!

Indrani Gill, John J. Crowley, or the Southwest Oncology Group,

San Antonio, Texas, USA We have developed a tolerable and effective

chemotherapeutic‘ regimen for easy out-patient administration to patients (uts) with advanced lunr! cancer. To take advantage‘bf the marked schedulk dependency of E and reported synergy with C, this regimen combines oral E and oral C, each at a dose of iit;

52 /m2 per day on days 1-14 of a 28 day cycle. To

pts have received at least one cycle and a total cles of treatment have been delivered to 15

using this regimen continue.

474

ABSTRACT WITHDRAWN